BD Stock Down Despite Making Progress in the Treatment of PAD Lesions

Becton, Dickinson and Company (BDX) announced the enrollment of the first patient in its XTRACT Registry, a multi-center study designed to assess the real-world performance of its Rotarex Catheter System for Peripheral Artery Disease (PAD). This dual-function device, combining atherectomy and thrombectomy, is expected to bolster BD's Peripheral Intervention business within a global PAD market projected to grow from $7.3 billion in 2024 to $11.3 billion by 2033. Despite this strategic milestone and the significant market opportunity, BDX shares experienced a nearly 3.8% decline following the announcement.

Analysis

Becton, Dickinson and Company (BDX) has initiated the XTRACT Registry, enrolling the first patient to evaluate its Rotarex Catheter System for Peripheral Artery Disease (PAD). This system, which combines atherectomy and thrombectomy functionalities, represents a strategic advancement for BD's Peripheral Intervention (PI) business unit. Despite this positive development, BDX shares experienced a nearly 3.8% decline following the announcement, contrasting with historical trends where product innovations typically boost top-line growth.

The XTRACT Registry, a multi-center study targeting 600 patients, is designed to generate crucial real-world evidence on the Rotarex system's safety and effectiveness. This initiative positions BD to capitalize on the growing global PAD market, which is estimated at $7.3 billion in 2024 and projected to reach $11.3 billion by 2033, driven by a 5.2% CAGR and increasing disease burden. BD's PI business already demonstrated strong growth in Q3 FY25, partly due to the Rotarex Atherectomy System.

Financially, BDX reported a 7.6% earnings surprise last quarter and boasts an earnings yield of 7.9%, surpassing the industry average of 6.6%. However, the stock has significantly underperformed, declining 21.8% over the past year compared to a 1.4% industry rise and a 13.9% gain for the S&P 500. This divergence between fundamental strength and market performance, coupled with a Zacks Rank #3 (Hold), suggests investor caution.

Key Decisions for Investors

• Monitor the XTRACT Registry's progress and initial data releases, as positive real-world evidence for the Rotarex system could be a significant catalyst for BDX's long-term growth in the expanding PAD market
• Evaluate BDX's current valuation metrics, such as its 7.9% earnings yield, against its recent 21.8% stock underperformance to assess if current market pricing reflects its fundamental strengths and future potential
• Consider the implications of the Zacks Rank #3 (Hold) and the broader market sentiment, which currently shows a mixed outlook despite strategic product advancements